Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem

European Journal of Clinical Pharmacology

Volumn 65, Issue 3, 2009, Pages 239-247

  Wang, Yixi ^a   Wang, Changxi ^a   Li, Jiali ^a   Wang, Xueding ^a   Zhu, Genglong ^a   Chen, Xiao ^a   Bi, Huichang ^a   Huang, Min ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cyclosporin; CYP3A5; Diltiazem; Genotype; MDR1; Renal transplantation

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A5; DILTIAZEM; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; AGED; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GENETIC POLYMORPHISM; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CALCIUM CHANNEL BLOCKERS; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, GENETIC; TIME FACTORS; YOUNG ADULT;

EID: 60549093838     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0577-4     Document Type: Article

References (39)

1. A Lindholm S Henricsson R Dahlqvist 1990 The effect of food and bile acid administration on the relative bioavailability of cyclosporine Br J Clin Pharmacol 29 541
2. SK Gupta LZ Benet 1990 High fat meals increase the clearance of cyclosporine Pharmaceut Res 7 46
3. WE Evans HL McLeod 2003 Pharmacogenomics Drug disposition, drug targets and side effect N Engl J Med 348 538 549
4. BD Kahan P Keown GA Levy A Fennerty J Dolben P Thomas 2002 Therapeutic drug monitoring of immunosuppressant drugs in clinical practice Clin Ther 24 330 350
5. KS Lown RR Mayo AB Leichtman A Fregin V Ivaskevicius E Conzelmann 1997 Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclpsporine Clin Pharmacol Ther 62 248 260
6. V Ozdemir W Kalow BK Tang AD Paterson SE Walker L Endrenyi 2000 Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method Pharmacogenetics 10 373 388
7. D Dai J Tang R Rose E Hodgson RJ Bienstock HW Mohrenweiser JA Goldstein 2001 Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos J Pharmacol Exp Ther 299 825 831
8. KS Yu JY Cho IJ Jang BK Tang AD Paterson SE Walker 2004 Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states Clin Pharmacol Ther 76 104 112
9. YF Hua J He G Chen D Wang Z Liu C Zhang LF Duan HH Zhou 2005 CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population Clin Chim Acta 353 187 192
10. AH Schinkel E Wagenaar CA Mol L van Deemter 1996 P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 97 2517 2524
11. C Cordon-Cardo JP O'Brien D Casals K Kobayashi H Suzuki K Anan S Ohno 1989 Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites Proc Natl Acad Sci USA 86 695 698
12. RB Kim BF Leake EF Choo AK Daly TI Khan HA Wynne F Kamali 2001 Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 189 199
13. S Mezzano C Flores L Ardiles S Yamano DJ Waxman 1998 Study of neoral kinetics in adult renal transplantation treated with diltiazem Transplant Proc 30 1660
14. JS Bleck C Thiesemann V Kliem M Vecsler R Loebstein S Almog 1996 Diltiazem increases blood concentration of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients Br J Clin Pharmacol 4 551
15. A Asberg H Christensen A Hartmann E Carlson E Molden KJ Berg 1999 Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients Eur J Clin Pharmacol 55 383 387
16. CM Clase K Mahalati BA Kiberd AJ Sadeque JJ Murray C Wandel RB Kim AJ Wood 2002 Adequate early cyclosporine exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling Am J Transplant 2 789 795
17. N Blin DW Stafford 1976 A general method for isolation of high molecular weight DNA from eukaryotes Nucleic Acids Res 3 2303 2308
18. S Fukuen T Fukuda H Maune SJ Mouly C Matheny MF Paine 2002 Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and*6, in a Japanese population Pharmacogenetics 12 331 334
19. M-M Fernando T Nakamura T Sakaeda N Ohmoto T Tamura N Aoyama 2001 MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity Pharmacogenetics 11 217 221
20. D Li G-L Zhang Y-Q Lou B Zhu GL Chen XP Chen 2007 Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups J Clin Pharm Ther 32 89 95
21. M Yuka N Tsutomu H Masanori S Toshiyuki T Takao A Nobuo S Toshiro G Akinobu M Masafumi K Masato Katsuhiko 2002 Effects of Polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects Biol Pharm Bull 25 1356 1359
22. I Abate M Ginard JM Gonzalez H Yonath D Peleg M Rotenberg 2000 Evaluati on of the AxSY M monoclonal cyclosporin assay and comparis on with radioimmunoassay Ther Drug Monit 22 474
23. P Kuehl J Zhang Y Lin J Lamba M Assem J Schuetz 2001 Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 383 391
24. V Haufroid M Mourad V van Kerckhove R Loebstein M Vecsler D Kurnik N Austerweil E Gak H Halkin 2004 The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transp lant patients Pharmacogenetics 14 147 154
25. A Dennis MD Hesselink IP Heiden JH You MJ Rieder FM Farin HW Wilkerson DK Blough G Cheng AE Rettie 2003 Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 245 254
26. YF Hu W Qiu ZQ Liu LJ Zhu ZQ Liu JH Tu D Wang Z Li J He GP Zhong G Zhou HH Zhou 2006 Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on Cyclosporine pharmacokinetics after renal transplantation ClinExp Phar Phys 33 1093 1098
27. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK (2008) Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol. PMID: 18636247
28. JS Bleck C Thiesemann V Kliem U Christians H Hecker H Reff U Frei M Westhoff-Bleck M Manns KF Sewing 1996 Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients Br J Clin Pharmacol 41 551 556
29. R Wacke B Drewelow EM Hehl A-K Riethling 1992 Measurement of cyclosporin A in whole blood by RIA, EMIT and FPIA: a comparative study Int J Clin Pharmacol Ther Toxicol 30 502 503
30. GJ Burcart A Los 1999 P-glycoprotein and drug therapy in organ transplantation J Clin Pharmacol 39 995 1005
31. I Cascorbi T Gerloff A Johne C Meisel S Hoffmeyer M Schwab E Schaeffeler M Eichelbaum U Brinkmann I Roots 2001 Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin Pharmacol Ther 69 169 174
32. S Hoffmeyer O Burk O vonRichter HP Arnold J BrockmoÈller A Johne 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 3473 3478
33. M Tanabe I Ieiri N Nagata K Inoue S Ito Y Kanamori M Takahashi Y Kurata J Kigawa S Higuchi N Terakawa K Otsubo 2001 Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene J Pharmacol Exp Ther 297 1137 1143
34. T Sakaeda T Nakamura M Horinouchi M Kakumoto N Ohmoto T Sakai Y Morita T Tamura N Aoyama M Hirai M Kasuga 2001 MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects Pharm Res 18 1400 1404
35. N Azarpira MH Aghdaie A Behzad-Behbahanie B Geramizadeh S Behzadi SA Malekhoseinie GH Raisjalal M Rahsaz A Pourgholami F Sagheb 2006 Association between Cyclosporine Concentration and Genetic Polymorphisms of CYP3A5 and MDR1 during the Early Stage after Renal Transplantation Exp Clin Transplant 4 416 419
36. W Wang XD Zhang DL Guan YP Lu LL Ma XP Hu P Zhang Y Wang X Chen 2005 Relationship between MDR1 polymorphism and blood concentration of cyclosporine A Chin Med J 118 2097 2100
37. CJ Foote W Greer BA Kiberd A Fraser J Lawen B Nashan P Belitsky 2006 MDR1 C3435T Polymorphisms correlate with cyclosporine levels in de novo renal recipients Trans Proc 38 2847 2849
38. I Mai E Störmer M Goldammer A Johne H Krüger K Budde I Roots 2003 MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients J Clin Pharm 43 1101 1107
39. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Edmund J (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporine disposition in heart transplant recipients. Pharmacogenetics 13:89-95